Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide before talc pleurodesis for malignant pleural effusion
IRCT20210915052492N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Mar 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in malignant pleural effusion (MPE) comparing Octreotide + talc pleurodesis with Placebo + talc pleurodesis (2 arms). Primary endpoints: Amount of discharge from the chest tube before pleurodesis, Amount of discharge from the chest tube after pleurodesis and 1 more. Started Mar 2020; status: completed.
02
Drugs
octreotide
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on IRCT20210915052492N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210915052492N1.